Trials / Unknown
UnknownNCT05296278
Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC
Efficacy and Biomarker Explanation of IBI-323 Combined With Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged Non-Small Cell Lung Cancer Who Failed From First Line Alectinib
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to explore the efficacy and biomarker explanation of IBI-323 combined with bevacizumab plus platinum based chemotherapy on ALK-rearranged non-small cell lung cancer who failed from first line Alectinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI-323 combined with bevacizumab plus Platinum | IBI-323 (30 mg/kg) ccombined with bevacizumab (15 mg/kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression |
Timeline
- Start date
- 2023-12-25
- Primary completion
- 2025-12-10
- Completion
- 2026-04-01
- First posted
- 2022-03-25
- Last updated
- 2024-01-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05296278. Inclusion in this directory is not an endorsement.